orntide

Orntide (also known as ORF 23541) is a synthetic decapeptide and a potent antagonist of the gonadotropin-releasing hormone (GnRH) receptor. Developed by Ortho Pharmaceutical, it was primarily investigated for its ability to suppress the pituitary-gonadal axis. By competitively binding to GnRH receptors in the anterior pituitary, orntide inhibits the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn leads to a rapid and reversible reduction in serum testosterone levels in males and estrogen levels in females. This pharmacological profile makes it a candidate for treating hormone-sensitive conditions such as prostate cancer, endometriosis, and uterine fibroids, as well as for use in controlled ovarian stimulation and male contraception. Clinical development reached Phase II in the 1990s, but the drug is no longer actively pursued for commercialization.

Other names

orntide acetateAc-D-2Nal-D-4ClPhe-D-3Pal-Ser-NicLys-D-NicLys-Leu-Ilys-Pro-D-Ala-NH2Ac-D2Nal-D-4ClPhe-D-3Pal-Ser-NicLys-D-NicLys-Leu-Ilys-Pro-D-Ala-NH2Ac-D 2Nal-D-4ClPhe-D-3Pal-Ser-NicLys-D-NicLys-Leu-Ilys-Pro-D-Ala-NH2